This HTML5 document contains 38 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n10http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB09000/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/drug/DB09000/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/drug/DB09000/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://www.drugs.com/international/
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB09000
rdf:type
n3:Drug
n3:description
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
n3:group
approved
owl:sameAs
n10:DB09000
dcterms:title
Cyamemazine
adms:identifier
n6:DB09000 n7:D07307 n8:Cyamemazine
n3:synthesisReference
U.S. Patent 2,877,224.
foaf:page
n15:cyamemazine.html
n3:IUPAC-Name
n4:271B63B5-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B63BB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B63BA-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B63B7-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B63B8-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B63B9-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B63B3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B63B4-363D-11E5-9242-09173F13E4C5 n4:271B63B1-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B63B2-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:N05AA06
n3:H-Bond-Acceptor-Count
n4:271B63C1-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B63C2-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B63BC-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B63BD-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B63BF-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B63BE-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B63C0-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
3546-03-0
n3:Bioavailability
n4:271B63C6-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B63C8-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B63C9-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B63CA-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B63C5-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B63C4-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B63C7-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B63B6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B63C3-363D-11E5-9242-09173F13E4C5